Moreover, assays for MDA and ROS indicated that RGFP966 only partially restored the capability of ACSL4 to promote lipid peroxidation and ferroptosis in prostate cancer cells (Fig. S9E, F). Here, ACSL4 is linked to prostate carcinoma.